Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.33 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | XBP1 | P17861 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725570 | 0.82 | KIF11 (0.46) | KIF11PTPN7DUSP3USP28USP25 | |
| SCHEMBL17049173 | 0.80 | PTPN2 (0.53) | PTPN2 | |
| SCHEMBL20496691 | 0.77 | NOTUM (0.31) | NOTUM | |
| SCHEMBL1315369 | 0.77 | PTPN1 (0.33) | USP28 | |
| SCHEMBL2034552 | 0.77 | PTPN1 (0.33) | USP28NPSR1 | |
| SCHEMBL2297172 | 0.77 | KIF11 (0.39) | KIF11ADRB2PTPN7DUSP3NOTUM | |
| SCHEMBL9227013 | 0.77 | NOTUM (0.36) | KIF11ADRB2NOTUMMAPTMEN1 | |
| SCHEMBL30416102 | 0.77 | NOTUM (0.36) | KIF11ADRB2NOTUMMAPTMEN1 | |
| SCHEMBL20496692 | 0.76 | NOTUM (0.30) | NOTUM | |
| SCHEMBL17930510 | 0.76 | SHBG (0.34) | MAPTMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552777-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240376079-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3621615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3621615-B1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2023-06-08 | — | — | US | disclosed |
| CN-110869017-B | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | 英安塔制药有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11560368-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2016-09-08 | — | — | US | disclosed |
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2016-09-08 | — | — | US | disclosed |
| EP-3055288-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-08-17 | — | — | EP | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-07-21 | — | — | US | disclosed |
| WO-2015073342-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073342-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051725-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015051496-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552777-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | AIFM1, BAD, IRAK1 | KIF11 3515/4885ADRB2 2539/4885PTPN7 267/4885 |
| US-20240376079-A1 | Apoptosis Signal-Regulating Kinase 1 Inhibitors and Methods of Use Thereof | BAD, CASP1, BAX | KIF11 1687/4885ADRB2 3318/4885PTPN7 291/4885 |
| US-20160207887-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR55 | KIF11 4383/4885ADRB2 146/4885PTPN7 1368/4885 |
| US-11560368-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | KIF11 1687/4885ADRB2 3318/4885PTPN7 291/4885 |
| US-12018017-B2 | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, CASP1, BAX | KIF11 1687/4885ADRB2 3318/4885PTPN7 291/4885 |
| US-20160257652-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | KIF11 4326/4885ADRB2 138/4885PTPN7 1866/4885 |
| US-20230174515-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | BAD, CASP1, BAX | KIF11 1687/4885ADRB2 3318/4885PTPN7 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.